Higher Cumulative Live Birth Rate but Also Higher Late Miscarriage Risk in Non-Obese Women with Polycystic Ovary Syndrome Undergoing the First IVF/ICSI Cycle
Simin Liu,Xiu Zhou,Huiying Jie,Zetong Zheng,Bing Cai,Qingyun Mai,Canquan Zhou
DOI: https://doi.org/10.2147/ijwh.s445021
2024-02-23
International Journal of Women s Health
Abstract:Simin Liu, 1, 2 Xiu Zhou, 1, 2 Huiying Jie, 1, 2 Zetong Zheng, 1, 2 Bing Cai, 1, 2 Qingyun Mai, 1– 3 Canquan Zhou 1– 3 1 Reproductive Medicine Center, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, People's Republic of China; 2 Guangdong Provincial Key Laboratory of Reproductive Medicine, Guangzhou, People's Republic of China; 3 Guangdong Provincial Clinical Research Center for Obstetrical and Gynecological Diseases, Guangzhou, People's Republic of China Correspondence: Canquan Zhou, Reproductive Medicine Center, The First Affiliated Hospital, Sun Yat-Sen University, No. 1 Zhongshan Second Road, Guangzhou, 510080, People's Republic of China, Fax +86 87330736, Email Purpose: To determine the impact of polycystic ovary syndrome on in vitro fertilization/intracytoplasmic sperm injection and embryo transfer outcomes while analyzing the influencing factors. Patients and Methods: A retrospective cohort study comprised 4839 patients who underwent their first cycle of IVF/ICSI treatment from January 2016 to December 2021. Cumulative pregnancy rates, cumulative live birth rates, and late miscarriage rates compared between the PCOS group and control group. Subgroup analysis and binary regression were used to analyze the influence of BMI on clinical outcomes among individuals diagnosed with PCOS. Results: Non-obese PCOS patients exhibited higher cumulative pregnancy rates, cumulative live birth rates, and late miscarriage rates compared to the control group with the normal BMI population (84.7% vs71.2%, P < 0.001; 74.1% vs 61.6%, P < 0.001; 4.1% vs 2.0%, P = 0.002), but there was no significant difference in early miscarriage rates between the two groups. Conclusion: Non-obese PCOS patients demonstrated a notably higher cumulative live birth rate but also a higher risk of late miscarriage compared to non-PCOS females with a normal BMI. Keywords: body mass index, cumulative live birth rate, in vitro fertilization, intracytoplasmic sperm injection, late miscarriage, polycystic ovary syndrome Polycystic Ovary Syndrome (PCOS) is a complex endocrine disorder characterized primarily by a combination of clinical features, including hyperandrogenism, anovulation, and the presence of polycystic ovaries. 1 The intricate physiopathology of PCOS remains elusive, with the complexity attributed to the intricate interplay of components, including genetic predisposition, neuroendocrine dysfunction, prenatal influences, and lifestyle factors. 2–5 The global prevalence of PCOS among women of childbearing age varies, ranging from 6% to 21%. 6–9 PCOS represents a significant contributor to ovulatory infertility, carrying substantial implications for those affected by the condition. 10,11 Additionally, PCOS frequently coexists with metabolic disorders such as obesity, hyperlipidemia, insulin resistance, further complicating its clinical landscape. 12,13 Assisted Reproductive Technology (ART), which includes approaches such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI), presents promising prospects for PCOS patients aiming to overcome their fertility challenges. 11,14 The Cumulative Live Birth Rate (CLBR), a metric that considers outcomes from both fresh embryo transfer cycles and frozen embryo transfer (FET) cycles, provides a more comprehensive measure for assessing the overall success of IVF/ICSI interventions. 15,16 The substantial response observed during ovarian stimulation in PCOS women contributes to an impressive CLBR of approximately 70%. 17 It is crucial to acknowledge that although PCOS patients may exhibit enhanced reproductive capacity, the presence of underlying metabolic disorders underscores the potential for an increased vulnerability to pregnancy complications and adverse perinatal outcomes. 18–21 While approximately 40–60% of PCOS patients are overweight or obese, 22,23 a clinically significant subset maintains a normal body mass index (BMI < 25 kg/m2). 24 These metabolic abnormalities extend beyond overweight or obese individuals with PCOS, impacting even those with a normal BMI. 25 Research has emphasized the adverse impact of obesity on IVF outcomes, including live birth rates and the risk of miscarriage. 26 However, there remains a notable scarcity of dedicated investigations specifically aimed at exploring the clinical outcomes of IVF/ICSI in individuals diagnosed with non-obese PCOS. Accordingly, we conducted a comprehensive evaluation of the clinical outcomes among a cohort of PCOS patients under -Abstract Truncated-
obstetrics & gynecology